ES2134197T3 - Vacunas contra el virus del herpes simplex vp16. - Google Patents

Vacunas contra el virus del herpes simplex vp16.

Info

Publication number
ES2134197T3
ES2134197T3 ES91914945T ES91914945T ES2134197T3 ES 2134197 T3 ES2134197 T3 ES 2134197T3 ES 91914945 T ES91914945 T ES 91914945T ES 91914945 T ES91914945 T ES 91914945T ES 2134197 T3 ES2134197 T3 ES 2134197T3
Authority
ES
Spain
Prior art keywords
herpes simplex
viruses
vaccines against
against herpes
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91914945T
Other languages
English (en)
Inventor
Rae Lynn Burke
Rose E Sekulovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2134197T3 publication Critical patent/ES2134197T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LAS COMPOSICIONES QUE SON UTILES PARA EL TRATAMIENTO DE INFECCIONES INDIVIDUALES CAUSADAS POR EL VIRUS DEL HERPES SIMPLEX (HSV) ESTAN DADAS, COMO LO ESTAN LOS METODOS PARA SU USO. ESTAS COMPOSICIONES ESTAN FORMADAS DE POLIPEPTIDOS INMUNOGENICOS LOS CUALES SE COMPRENDEN DE UN EPITOPO DE HSV VP16. ELLOS TAMBIEN PUEDEN COMPRENDERSE DE UN EPITOPE DE UNA GLICOPROTEINA DE HSV, Y METODOS Y COMPOSICIONES USADOS EN LA PRODUCCION DE LOS POLIPEPTIDOS.
ES91914945T 1990-08-02 1991-07-30 Vacunas contra el virus del herpes simplex vp16. Expired - Lifetime ES2134197T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56152890A 1990-08-02 1990-08-02

Publications (1)

Publication Number Publication Date
ES2134197T3 true ES2134197T3 (es) 1999-10-01

Family

ID=24242345

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91914945T Expired - Lifetime ES2134197T3 (es) 1990-08-02 1991-07-30 Vacunas contra el virus del herpes simplex vp16.

Country Status (12)

Country Link
US (2) US5714152A (es)
EP (1) EP0541692B1 (es)
JP (3) JP3005292B2 (es)
AT (1) ATE179614T1 (es)
CA (1) CA2088600C (es)
DE (1) DE69131200T2 (es)
DK (1) DK0541692T3 (es)
ES (1) ES2134197T3 (es)
GR (1) GR3030834T3 (es)
IE (1) IE912744A1 (es)
PT (1) PT98565B (es)
WO (1) WO1992002251A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9119940D0 (en) * 1991-09-18 1991-10-30 Hare Peter F J O Polypeptide inhibitor of viral replication
US5965354A (en) * 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
CA2291010A1 (en) 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6087166A (en) * 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
TR200002608T2 (tr) * 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
CN1348463A (zh) * 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
US6824292B2 (en) * 1999-01-06 2004-11-30 Armament Systems And Procedures, Inc. LED flashlight with clip opposite LED
US6569616B1 (en) * 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
CA2454750C (en) 2001-07-31 2012-09-18 David M. Koelle Immunologically significant herpes simplex virus antigens and methods for using same
KR100420501B1 (ko) * 2001-09-26 2004-03-02 한국지질자원연구원 벤토나이트로부터 몬모릴로나이트 광물의 분리·회수 방법
ATE541562T1 (de) * 2002-06-17 2012-02-15 Taro Pharmaceuticals Usa Inc Ibuprofen-suspension
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (en) 2009-04-03 2013-05-01 Univ Washington ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
US10745931B1 (en) 2019-08-14 2020-08-18 Premises Innovations Llc Self-rightening post system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
EP0133063B1 (en) * 1983-06-23 1987-01-07 Stanley Dr. Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
JPS6051120A (ja) * 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
US4642333A (en) * 1983-09-16 1987-02-10 Stanley Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein B of herpes virus types 1 and 2
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
EP0628633B1 (en) * 1984-04-06 2003-01-08 Chiron Corporation Recombinant herpes simplex gB-gD vaccine
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPH0668B2 (ja) * 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
EP0289550B1 (en) * 1986-10-20 1996-04-10 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
GB8917029D0 (en) * 1989-07-25 1989-09-13 Marie Curie Memorial Foundatio Polypeptide inhibitor of viral replication

Also Published As

Publication number Publication date
EP0541692A1 (en) 1993-05-19
CA2088600C (en) 1999-11-16
EP0541692A4 (en) 1993-12-08
JP2002136297A (ja) 2002-05-14
GR3030834T3 (en) 1999-11-30
ATE179614T1 (de) 1999-05-15
US5714152A (en) 1998-02-03
JP3005292B2 (ja) 2000-01-31
CA2088600A1 (en) 1992-02-03
JPH06502989A (ja) 1994-04-07
DE69131200T2 (de) 1999-12-09
PT98565B (pt) 1999-01-29
US5795579A (en) 1998-08-18
DE69131200D1 (en) 1999-06-10
EP0541692B1 (en) 1999-05-06
DK0541692T3 (da) 1999-11-01
IE912744A1 (en) 1992-02-12
WO1992002251A1 (en) 1992-02-20
PT98565A (pt) 1992-06-30
JPH11308998A (ja) 1999-11-09

Similar Documents

Publication Publication Date Title
ES2103966T3 (es) Uso de una timosina en el tratamiento de hepatitis c.
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ES2179105T3 (es) Adyuvantes proteinicos.
ES2126620T3 (es) Retrovirus del grupo de los vih y su utilizacion.
CO4910170A1 (es) Vacunas
ES2081102T3 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
ES2191052T3 (es) Vacuna polinucleotida contra el virus del papiloma.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
PE20211307A1 (es) ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
MX9203972A (es) Compuestos inhibidores de la proteasa codificada por el virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulado farmaceutico que los contiene.
ES2044849T3 (es) Un procedimiento para preparar un glicosido de flavona.
ES2185760T3 (es) Composicion farmaceutica para el tratamiento del herpes.
ES2082872T3 (es) Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol.
ES2161412T3 (es) Paquete de vacuna que comprende un recipiente con compuestos vacunales liofilizados.
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
ES2105684T3 (es) Derivados insaturados de fosfonato de purinas y pirimidinas.
ES495939A0 (es) Un procedimiento de preparacion de una vacuna de virus vivosde la peritonitis infecciosa de los felinos
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
DE69034166D1 (de) Azellulärer Impfstoff
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
TR199801289T2 (en) Terap�tik bile�ikler.
ES2058100T3 (es) Vacuna combinada.
ES2182847T3 (es) Nucleosidos y nucleotidos de anillo expandido.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 541692

Country of ref document: ES